CJC-1295 research centres on a straightforward but often overstated question: what happens when a modified growth hormone-releasing hormone analogue is designed to remain in circulation for longer? The available literature supports measurable effects on endocrine signalling in controlled settings. It does not establish clinical outcomes, personal-use safety, or therapeutic value.
For researchers sourcing this type of material, the practical task is therefore twofold. First, distinguish the long-acting DAC-containing material studied in the cited papers from products labelled “CJC-1295 No DAC”. Second, assess whether the material’s identity and analytical documentation are suitable for the intended laboratory work.
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary to release growth hormone. It is based on modified GRF(1-29), a shortened and stabilised form of the first 29 amino acids of GHRH.
The defining feature of the original CJC-1295 construct is its Drug Affinity Complex, commonly shortened to DAC. This chemical feature is intended to bind circulating albumin, extending exposure relative to an unmodified or shorter-acting peptide. That extended exposure is the central scientific distinction behind the CJC-1295 name in the published literature.
GHRH signalling is physiologically pulsatile and interacts with other regulators, including somatostatin, ghrelin, sleep, nutritional state and age. A long-acting analogue may therefore be useful for studying how sustained receptor stimulation changes the pattern and duration of downstream hormone release. It should not be treated as a simple substitute for normal physiology.
CJC-1295 research and the GHRH pathway
At the molecular level, GHRH binds the GHRH receptor on anterior pituitary somatotroph cells. Receptor activation is associated with cyclic adenosine monophosphate signalling and promotes growth hormone secretion. Growth hormone can then influence hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), alongside a wider network of metabolic and growth-related signals.
This pathway makes CJC-1295 relevant to several research questions. These include receptor pharmacology, the time course of endocrine responses, peptide stabilisation strategies, albumin-binding delivery chemistry, and the relationship between growth hormone secretion and circulating IGF-1. Each question requires a different experimental design and different controls.
For example, an assay investigating receptor activity may prioritise sequence confirmation, solvent compatibility and a carefully selected comparator peptide. A project examining prolonged exposure will also need a design capable of separating peptide stability from albumin-mediated persistence. Neither type of study can, by itself, support a claim about clinical benefit.
DAC CJC-1295 versus related GHRH analogues
Commercial terminology can be imprecise. Some materials are described as “CJC-1295 no DAC”, even though the DAC is what historically differentiated CJC-1295 from modified GRF(1-29) in the scientific literature. Researchers should request the exact peptide identity, sequence or molecular information rather than relying on a shortened product name.
| Research feature | CJC-1295 with DAC | Modified GRF(1-29) or “no DAC” terminology |
|---|---|---|
| Defining design feature | Includes an albumin-binding Drug Affinity Complex | Does not include the DAC feature |
| Intended pharmacological distinction | Prolonged circulating exposure | Shorter exposure profile is generally expected |
| Procurement question | Is the DAC-containing identity confirmed analytically? | What exact sequence and modification are supplied? |
| Literature interpretation | Most directly related to published CJC-1295 studies | Cannot automatically be treated as equivalent to DAC CJC-1295 |
The comparison is not merely semantic. Differences in molecular modification can affect molecular mass, chromatographic behaviour, stability considerations and the relevance of a cited paper to the material on the bench.
What human research has reported
Teichman and colleagues (2006) reported two randomised, placebo-controlled, double-blind trials lasting 28 and 49 days in healthy adults aged 21–61. The investigators observed sustained increases in growth hormone and IGF-1 after exposure to the long-acting CJC-1295 analogue. These results concern the tested formulation, population and hormone measurements; they are not a study of the No DAC product sold here.
The study establishes endocrine activity under its experimental conditions. It does not demonstrate improved performance, slowed ageing or a favourable long-term health outcome.
A separate study by Ionescu and Frohman (2006) examined overnight hormone measurements in healthy men before and one week after the albumin-binding analogue. Growth hormone pulsatility persisted, while trough and mean growth hormone and IGF-1 increased. This provides information about secretion patterns, not proof of clinical benefit or equivalence to a No DAC material.
The distinction matters because hormone concentrations are surrogate measures. A shift in a biomarker can be useful for mechanistic research while remaining insufficient to answer questions about benefit, risk, durability, target populations or comparative clinical value. Study population, observation period, formulation and experimental conditions all limit how far a result can be generalised.
Published human work should also be read alongside its scope. Early pharmacology studies are designed to characterise exposure and biological activity, not to resolve every question that would be required for therapeutic decision-making. Researchers should avoid converting a finding about growth hormone or IGF-1 into a broader claim that the original study did not test.
Evidence limitations worth keeping in view
The CJC-1295 literature is narrower than many online discussions suggest. Mechanistic plausibility and measurable endocrine activity do not remove the need for well-controlled, compound-specific research.
Several limitations recur. First, GHRH-pathway effects can vary with baseline physiology and the timing of measurement. Second, changes in growth hormone and IGF-1 do not capture all downstream biological effects. Third, results obtained with DAC CJC-1295 cannot be assumed to apply to a peptide sold under similar terminology but carrying a different modification. Finally, preclinical, in vitro and human evidence answer different questions and should be labelled accordingly.
Animal and cell studies can help investigate receptor signalling, tissue-specific responses or peptide handling under controlled conditions. Their value lies in mechanism and hypothesis testing. They cannot establish outcomes in humans. Likewise, a small human endocrine study provides more direct translational information than a cell model, but it remains limited to its own endpoints and design.
Documentation priorities when sourcing CJC-1295 material
For laboratory procurement, analytical evidence should be assessed before convenience of format. Our guide to reading a peptide certificate of analysis explains the document checks. A report can be useful, but it is not a single universal proof of quality. It should identify the relevant batch, name the analyte clearly, and provide results that can be interpreted in the context of the method used.
High-performance liquid chromatography, or HPLC, and mass spectrometry answer different questions. HPLC is commonly used to assess the chromatographic profile and reported purity under stated conditions. Mass spectrometry helps support molecular identity by measuring mass-to-charge signals consistent with the expected compound. A strong procurement review considers both the claimed content and the evidence supporting identity; purity and content are not interchangeable terms.
For CJC-1295 specifically, confirm whether documentation corresponds to a DAC-containing compound or a No DAC material, and match that identity to the planned experiment. The stated molecular mass, nomenclature and batch identifier should align. If the study requires quantitative work, researchers should also consider whether the method is suitable for the intended matrix and whether an appropriate reference standard is required.
Handling requirements should be based on the supplier’s product-specific information and the stability needs of the actual protocol. It is not scientifically sound to assume one storage condition or shelf life applies to every peptide, format or prepared sample. Record keeping matters here: batch numbers, receipt condition, storage history and preparation details can all affect reproducibility.
Check the product against the research question
Revitalise’s CJC-1295 No DAC 5mg Research Vial is listed as a No DAC product. The 5mg label describes the stated vial contents, not a dose or a prepared concentration. It should not be presented as the same material tested in the long-acting CJC-1295 studies above. Confirm the supplied identity and batch documentation before selecting it for laboratory work.
Interpreting the evidence
CJC-1295 remains a useful subject for endocrine and peptide-delivery research because its DAC design provides a defined way to investigate prolonged GHRH receptor stimulation. The strongest reading of the evidence is also the most disciplined one: published work demonstrates endocrine activity under particular study conditions, while broader therapeutic and personal-use claims remain unsupported by that evidence.
The products sold by Revitalise are supplied for laboratory research only, not human or veterinary use. Before selecting a research format, review the compound-specific batch documentation, verify the precise molecular identity, and ensure that the planned work matches the limits of the available evidence.